ReviewOncogene2004
PML nuclear bodies and apoptosis.
Review in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 163 citations in OpenAlex.
- Article
- Interspecies Differences in Cytomegalovirus Inhibition by Cardiac Glycosides-A Unique Role of the Alpha3 Isoform of the NaViruses · 2025Article
- Article
- Regulation of SUMOylation on RNA metabolism in cancers.Frontiers in molecular biosciences · 2023Review
- Manipulation of Promyelocytic Leukemia Protein Nuclear Bodies by Marek's Disease Virus Encoded US3 Protein Kinase.Microorganisms · 2021Article
- JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.The Journal of experimental medicine · 2021Article
- Article
- DAXX in cancer: phenomena, processes, mechanisms and regulation.Nucleic acids research · 2019Review
- E1B-55K-Mediated Regulation of RNF4 SUMO-Targeted Ubiquitin Ligase Promotes Human Adenovirus Gene Expression.Journal of virology · 2018Article
- Differentiation therapy revisited.Nature reviews. Cancer · 2018Review
- Promyelocytic Leukemia Restricts Enterovirus 71 Replication by Inhibiting Autophagy.Frontiers in immunology · 2018Article
- PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53.Oncogene · 2016Article
- Article
- Assembly of Epstein-Barr Virus Capsid in Promyelocytic Leukemia Nuclear Bodies.Journal of virology · 2015Article
- Cellular promyelocytic leukemia protein is an important dengue virus restriction factor.PloS one · 2015Article
- Extrinsic apoptosis is impeded by direct binding of the APL fusion protein NPM-RAR to TRADD.Molecular cancer research : MCR · 2014Article
- Topoisomerase II and leukemia.Annals of the New York Academy of Sciences · 2014Review
- Virion factors that target Daxx to overcome intrinsic immunity.Journal of virology · 2013Review
- Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.The Journal of biological chemistry · 2013Article
- Control of human adenovirus type 5 gene expression by cellular Daxx/ATRX chromatin-associated complexes.Nucleic acids research · 2013Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Promyelocytic leukaemia nuclear bodies (PML NBs) are structured protein complexes associated with the nuclear matrix. PML constitutes the scaffold component of NBs and recruits onto these domains a striking variety of proteins, many of which are involved in apoptosis control. Several reports have directly implicated PML in apoptosis and senescence, but the mechanisms by which these are conveyed are still largely unsettled. Recruitment of partner proteins onto NBs is regulated by PML sumolation, a specific post-translational modification also found in many NB-associated proteins. Among these, several are implicated in transcription repression or activation, like the transcriptional repressor Daxx or the transcriptional activator P53. Whether NBs constitute platforms where active sites of enzymatic modifications are carried out, as suggested for P53, sites of intranuclear protein sequestration, as proposed for Daxx or organelles specialized in catabolism, is still debated. A variety of stress-related signalling pathways dramatically modulate the formation of PML NBs, which may provide a clue as to their physiological function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.